Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/222106
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMarín Jiménez, Ignacio-
dc.contributor.authorCarpio, Daniel-
dc.contributor.authorHernández, Vicent-
dc.contributor.authorMuñoz, Fernando-
dc.contributor.authorZatarain Nicolás, Eduardo-
dc.contributor.authorZabana, Yamile-
dc.contributor.authorMañosa, Míriam-
dc.contributor.authorRodríguez Moranta, Francisco-
dc.contributor.authorBarreiro de Acosta, Manuel-
dc.contributor.authorGutiérrez Casbas, Ana-
dc.date.accessioned2025-07-08T10:45:19Z-
dc.date.available2025-07-08T10:45:19Z-
dc.date.issued2024-11-28-
dc.identifier.issn1578-9519-
dc.identifier.urihttps://hdl.handle.net/2445/222106-
dc.description.abstractCardiovascular diseases (CVD) are the leading cause of death worldwide. Therefore, it is essential to understand their relationship and prevalence in different diseases that may present specific risk factors for them. The objective of this document is to analyze the specific prevalence of CVD in patients with inflammatory bowel disease (IBD), describing the presence of classical and non-classical cardiovascular risk factors in these patients. Additionally, we will detail the pathophysiology of atherosclerosis in this patient group and the different methods used to assess cardiovascular risk, including the use of risk calculators in clinical practice and different ways to assess subclinical atherosclerosis and endothelial dysfunction. Furthermore, we will describe the potential influence of medication used for managing patients with IBD on cardiovascular risk, as well as the potential influence of commonly used drugs for managing CVD on the course of IBD. The document provides comments and evidence-based recommendations based on available evidence and expert opinion. An interdisciplinary group of gastroenterologists specialized in IBD management, along with a consulting cardiologist for this type of patients, participated in the development of these recommendations by the Spanish Group of Work on Crohn's Disease and Ulcerative Colitis (GETECCU).-
dc.format.extent33 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier BV-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.gastrohep.2024.502314-
dc.relation.ispartofGastroenterología y Hepatología, 2024, vol. 48, num. 5, p. 502314-
dc.relation.urihttps://doi.org/10.1016/j.gastrohep.2024.502314-
dc.rightscc by-nc-nd (c) Marín Jiménez, Ignacio et al., 2024-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationMalaltia de Crohn-
dc.subject.classificationColitis ulcerosa-
dc.subject.classificationMalalties cardiovasculars-
dc.subject.otherCrohn's disease-
dc.subject.otherUlcerative colitis-
dc.subject.otherCardiovascular diseases-
dc.titleDocumento de posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la enfermedad cardiovascular en los pacientes con enfermedad inflamatoria intestinal-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2025-06-26T09:34:15Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
1-s2.0-S0210570524003273-main.pdf4.7 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons